Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.67 |
| ▸ | PNMT | P11086 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8500210 | 0.88 | PNMT (0.52) | TAAR1PNMTCYP3A4CYP1A2GLA | |
| SCHEMBL3840980 | 0.83 | TAAR1 (0.67) | TAAR1PNMTCYP1A2CYP2A6GLA | |
| SCHEMBL109221 | 0.83 | CYP3A4 (0.52) | TAAR1PNMTCYP3A4ALDH1A1NPSR1 | |
| SCHEMBL29487211 | 0.83 | CYP3A4 (0.52) | TAAR1PNMTCYP3A4ALDH1A1NPSR1 | |
| SCHEMBL8338503 | 0.81 | SIGMAR1 (0.47) | TAAR1PNMTCYP3A4CYP1A2GLA | |
| Hydrochloric Acid SCHEMBL4725966 | 0.81 | CSNK2A1 (0.53) | TAAR1PNMTCYP3A4ALDH1A1NPSR1 | |
| SCHEMBL9889567 | 0.81 | TAAR1 (0.49) | TAAR1PNMTCYP3A4CYP1A2CYP2A6 | |
| SCHEMBL184185 | 0.80 | TAAR1 (1.00) | TAAR1PNMTCYP1A2GLASMN1; SMN2 | |
| SCHEMBL718078 | 0.80 | TAAR1 (0.56) | TAAR1PNMTCYP1A2CYP2A6KDM4E | |
| SCHEMBL18553016 | 0.79 | TAAR1 (0.45) | TAAR1PNMTCYP3A4CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| EP-4499629-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023183919-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183919-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2021016254-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-10857155-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10406165-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| WO-2018169777-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180264000-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2018-09-20 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180264000-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | GSPT1, GSPT2, GGT1 | TAAR1 3012/4885PNMT 3301/4885CYP3A4 4822/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | TAAR1 4576/4885PNMT 545/4885CYP3A4 1560/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | TAAR1 4367/4885PNMT 4634/4885CYP3A4 308/4885 |
| US-10857155-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | GSPT1, GSPT2, GGT1 | TAAR1 3012/4885PNMT 3301/4885CYP3A4 4822/4885 |
| US-10406165-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | GSPT1, GSPT2, GGT1 | TAAR1 3012/4885PNMT 3301/4885CYP3A4 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.